Inventiva (NASDAQ:IVA) Shares Gap Up on Analyst Upgrade

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s share price gapped up prior to trading on Tuesday after Leerink Partnrs upgraded the stock to a strong-buy rating. The stock had previously closed at $5.45, but opened at $5.71. Inventiva shares last traded at $5.6260, with a volume of 120,111 shares changing hands.

A number of other brokerages also recently issued reports on IVA. Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 price target on shares of Inventiva in a report on Tuesday, September 30th. Wolfe Research upgraded shares of Inventiva to a “strong-buy” rating in a research note on Thursday, November 6th. Wall Street Zen upgraded shares of Inventiva to a “hold” rating in a research report on Saturday, October 18th. UBS Group initiated coverage on Inventiva in a research report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, HC Wainwright boosted their target price on Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $16.00.

Hedge Funds Weigh In On Inventiva

Several institutional investors and hedge funds have recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC raised its position in Inventiva by 54.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock worth $50,000 after purchasing an additional 5,843 shares during the period. Creative Planning bought a new position in shares of Inventiva during the second quarter valued at about $32,000. NewEdge Advisors LLC bought a new position in shares of Inventiva during the third quarter valued at about $116,000. Finally, Millennium Management LLC purchased a new position in shares of Inventiva in the third quarter worth about $649,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Stock Up 3.8%

The business has a 50 day moving average price of $4.35 and a two-hundred day moving average price of $4.50.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.